Integrated Research (ASX: IRI) revenue drops as Iris and Prognosis Elevate face FY2027 monetisation test

Integrated Research Limited (ASX: IRI) expects FY2026 statutory revenue of between A$56 million and A$58 million, representing a decline of approximately 17% as weaker software renewals and a softer second-half new-business contribution weighed on performance. Pro forma revenue, which adjusts for the timing of licence revenue recognition, is expected to fall about 13% to between A$64 million and A$66 million. The global enterprise observability software provider anticipates an EBITDA loss of A$2 million to A$4 million, although management said second-half EBITDA improved modestly from the first half. The counterweight is Integrated Research’s cash balance, which increased 27% to A$51.7 million at June 30, 2026, placing cash unusually close to the company’s approximately A$53 million market capitalisation. The central tension is whether this balance-sheet protection can give Integrated Research enough time to commercialise Iris, Prognosis Elevate and its wider product-led growth strategy before customer churn and subdued new sales weaken the recurring revenue base further.

Integrated Research shares closed at A$0.295 on July 24, down 3.28% during the session after trading between A$0.290 and A$0.305. The stock remained approximately 3.5% above its July 17 close and 5.4% above its June 24 level, but was still about 41% below its A$0.50 52-week high. The mixed performance suggests that investors recognise the value of the cash balance and new product pipeline while remaining unconvinced that the company has reached a sustainable revenue inflection point.

Why did Integrated Research’s FY2026 revenue fall despite investment in new software products?

Integrated Research attributed the revenue decline principally to a softer renewals book and lower new-business contribution during the second half. That combination is more important than a single weak reporting period because it affects both sides of the recurring software model. Lower renewal revenue suggests that contracts reaching the end of their terms did not all renew at the same value, while reduced new-business contribution means fresh customer and expansion sales were not sufficient to replace the revenue lost through churn.

The company expects statutory revenue to fall approximately 17% to between A$56 million and A$58 million. At the midpoint of A$57 million, the decline implies that Integrated Research generated roughly A$11.7 million less revenue than would be suggested by the prior-year comparison.

Pro forma revenue is expected to range from A$64 million to A$66 million, down approximately 13%. Integrated Research uses pro forma revenue to reflect licence revenue on a basis intended to provide a clearer comparison of underlying commercial activity where accounting recognition timing can produce volatility. The fact that both statutory and pro forma revenue declined indicates that the weakness was not merely an accounting timing issue.

New-business growth remained below the level needed to offset recurring revenue churn. This is the most important commercial issue emerging from the update. Integrated Research can continue launching products and generating demonstrations, trials and customer conversations, but the financial recovery depends on signed contracts becoming recognised revenue at a rate greater than contract expirations and reductions.

The first-half result had already revealed pressure. Revenue for the six months ended December 31, 2025, decreased 2% to A$28.3 million, while Integrated Research recorded an EBITDA loss of A$3.1 million and a statutory net loss of A$1.5 million. New-client licence revenue increased, but higher expected credit-loss provisions and ongoing product investment limited the benefit to reported earnings.

The full-year trading update indicates that second-half revenue did not accelerate sufficiently to restore annual growth. Management said EBITDA improved modestly during the second half, but revenue recovery remains the more consequential FY2027 challenge.

What does the A$2 million to A$4 million EBITDA loss reveal about the product-led reset?

Integrated Research expects FY2026 EBITDA to fall within a loss range of A$2 million to A$4 million. At the midpoint, the company would report an EBITDA loss of approximately A$3 million, equivalent to a negative margin of about 5.3% on midpoint statutory revenue.

The expected loss reflects more than weaker sales. Integrated Research said earnings were also affected by expected credit losses and foreign exchange movements. Expected credit losses relate to the probability that some customer receivables may not be collected in full, while currency movements can affect an Australian company that earns and incurs significant amounts across international markets.

These factors complicate the underlying performance assessment. Credit-loss provisions and foreign exchange changes may fluctuate, but the company cannot depend on their reversal to establish a profitable business model. Sustainable recovery must come from higher recurring revenue, improved sales productivity and operating costs that grow more slowly than revenue.

Management’s decision to continue investing during weaker trading reflects a deliberate product-led growth strategy. Integrated Research is attempting to modernise a business historically built around its Prognosis software platform by adding cloud-delivered services, artificial intelligence and expanded payments and collaboration capabilities.

This strategy creates a familiar software-company tension. Reducing investment could protect short-term earnings but slow the transition toward products that customers increasingly expect to consume through cloud and managed-service models. Maintaining investment protects the long-term opportunity but prolongs losses if new products do not commercialise quickly.

Integrated Research’s A$51.7 million cash position gives it more room to manage this tension than a similarly sized loss-making company dependent on repeated equity raisings. However, balance-sheet strength does not remove the need for commercial discipline. Product development must eventually result in recurring sales, stronger retention and improved customer lifetime value.

The company has indicated that FY2027 priorities will include accelerating the monetisation of newer products, expanding client-led innovation and converting product interest into measurable revenue. These priorities are directionally appropriate, but investors will need contract and revenue evidence rather than another year of platform-development milestones.

Why is Integrated Research’s A$51.7 million cash balance so important to the ASX valuation?

Integrated Research ended FY2026 with A$51.7 million in cash, an increase of 27% from the previous year. The cash increase is striking because it occurred during a year in which revenue declined and EBITDA remained negative.

With approximately 180.6 million ordinary shares on issue, the cash balance equates to roughly A$0.286 per share. Integrated Research closed at A$0.295, meaning reported cash represented approximately 97% of the share price and market capitalisation at the July 24 close.

That comparison will attract investors looking for balance-sheet-supported technology companies, but it must be interpreted carefully. Cash is not the same as liquidation value, and it is not automatically available for shareholder distributions. Integrated Research must fund employees, product development, sales operations, customer support, working capital and any contractual liabilities.

The company may also have lease liabilities, provisions and other obligations that reduce the economic value of gross cash. A proper enterprise-value calculation requires the complete audited balance sheet rather than comparing cash with market capitalisation in isolation.

Nevertheless, the cash position materially reduces immediate funding risk. Integrated Research does not appear dependent on a discounted equity raising simply to maintain its current product programme. That flexibility gives management time to improve renewals, commercialise new products and decide whether capital should be directed toward organic growth, acquisitions, buybacks or dividends.

The downside is that a large cash balance can conceal weak operating economics for a period. A company may appear inexpensive relative to cash while steadily consuming that cash through recurring losses. Investors should therefore track the rate of cash generation or consumption rather than treating the June 30 balance as a permanent valuation floor.

Integrated Research’s cash increased during FY2026, suggesting that statutory EBITDA alone does not capture the company’s cash movements. Licence collections, working-capital movements, delayed expenditure and other balance-sheet changes may have contributed. The audited FY2026 cash-flow statement will be necessary to understand how much of the increase came from sustainable operating cash conversion.

Can Iris and Prognosis Elevate restore growth in enterprise observability revenue?

Integrated Research’s product strategy centres on Prognosis, its platform for monitoring and analysing business-critical communications, payments and computing infrastructure. The company serves enterprises operating complex environments that may combine Microsoft Teams, Cisco, Avaya, Genesys, payment switches and HPE NonStop systems.

Iris is an artificial intelligence assistant embedded within Prognosis. Integrated Research designed the product to allow users to question complex observability data in natural language rather than manually navigating multiple dashboards. The company says Iris can surface patterns, identify performance issues and guide users toward potential actions while leaving operational control with human teams.

Prognosis Elevate represents a second part of the transition. It delivers Integrated Research’s observability platform as a managed, subscription-based cloud service. The product is intended for organisations that want the functionality of Prognosis without maintaining the underlying infrastructure and upgrade process themselves.

Elevate may improve the accessibility of Integrated Research’s technology by reducing deployment complexity. It may also create a more predictable subscription model and allow customers to receive product upgrades, including Iris capabilities, through a managed environment.

The strategic logic is credible. Enterprise information technology is becoming more fragmented as organisations operate combinations of cloud, on-premises and hybrid systems. Communications and payment environments can involve multiple vendors, increasing the difficulty of identifying the source of service degradation or failed transactions.

Integrated Research’s specialist knowledge could differentiate it from broad observability platforms that focus primarily on applications, infrastructure logs and developer workflows. The company’s products target communications quality, payment performance and HPE NonStop environments where downtime and transaction failures can carry significant operational costs.

The unresolved issue is monetisation. Iris and Elevate were launched during FY2026, but the annual revenue decline shows that new products have not yet offset weakness in the established contract base. Product launches create commercial options, not automatic revenue.

Integrated Research must demonstrate that customers will purchase Iris-related capabilities, migrate to Elevate or expand their use of Prognosis at prices that improve total contract value. Successful conversion would give the company a clearer recurring-revenue narrative. Slow adoption would leave it carrying development and cloud-service costs without sufficient revenue growth.

How does cautious enterprise AI spending affect Integrated Research’s FY2027 recovery?

Integrated Research is launching artificial intelligence functionality at a time when enterprise customers are interested in AI but increasingly selective about deployment. Technology buyers are moving beyond experimental enthusiasm and asking whether AI products reduce operating costs, improve response times or prevent measurable business disruption.

This more disciplined environment can help a specialist provider when its technology addresses a defined operational problem. Iris does not need to compete as a general-purpose chatbot. Its commercial case rests on helping communications and information technology teams interpret observability data more quickly across complex vendor environments.

However, a specialised AI product must still pass security, governance, accuracy and procurement reviews. Large financial institutions, government agencies, healthcare organisations and other regulated customers may move cautiously before allowing artificial intelligence systems to analyse operational data or recommend actions.

These approval processes can extend sales cycles. They may also explain why product innovation does not immediately appear in reported revenue, even when customers express interest.

Integrated Research can reduce this adoption barrier by embedding Iris within the existing Prognosis platform and making it available through Elevate. Existing customers already familiar with the underlying data and monitoring environment may be more willing to test additional capabilities than entirely new customers evaluating a standalone artificial intelligence platform.

The installed base is therefore both an opportunity and a warning. Long-standing customer relationships provide an audience for cross-selling, but the softer renewals book shows that historical customer loyalty cannot be assumed. New capabilities must reinforce the value of the core platform and improve renewal economics rather than distracting management from existing customers.

The strongest FY2027 signal would be an improvement in renewal rates accompanied by disclosed customer adoption of Iris or Elevate. That combination would show that product development is strengthening the recurring base rather than merely adding another layer of expenditure.

Why did Integrated Research shares fall despite cash approaching the market capitalisation?

Integrated Research shares declined 3.28% to A$0.295 on July 24, although the stock traded as high as A$0.305 during the session. Trading volume reached approximately 450,000 shares, materially above several quieter sessions during the preceding weeks.

The negative close indicates that investors placed greater weight on the revenue decline and negative EBITDA than on the cash increase. That reaction is understandable because a software company’s long-term value depends on its ability to generate recurring earnings, not merely preserve capital.

The stock’s broader performance is less uniformly negative. Integrated Research gained approximately 3.5% over the five trading sessions from July 17 and about 5.4% from June 24. It was also trading roughly 9.3% above its A$0.27 52-week low.

However, the stock remained 29.8% lower over 12 months and approximately 41% below its A$0.50 annual high. The valuation therefore reflects a company with considerable liquidity but limited market confidence in near-term commercial execution.

A cash-backed valuation can support the share price during a turnaround, but it is rarely sufficient to produce a durable rerating. Investors generally require evidence that management can stabilise revenue and move EBITDA toward breakeven without depleting the balance sheet.

The current valuation creates asymmetric possibilities. Successful product monetisation could produce a significant reassessment because the market assigns relatively little value above cash to the operating business. Continued revenue decline could instead turn the apparent cash support into a shrinking asset as operating losses and investment consume liquidity.

Which FY2027 proof points will determine whether Integrated Research’s reset is succeeding?

Integrated Research is scheduled to release its preliminary FY2026 results on August 25, followed by the annual report in October. Those documents should provide more precise revenue, EBITDA, operating cash flow, receivables, credit-loss provisions, foreign exchange impacts and product-development expenditure.

The renewal rate will be one of the most important operating indicators. Management must show that the weaker FY2026 renewals book was a cyclical timing issue or a manageable customer-specific problem rather than evidence of structural pressure on Prognosis.

New-business total contract value will provide the second major test. Integrated Research needs new-customer and expansion contracts to exceed churn consistently. One or two major enterprise wins could improve sentiment, but sustained recovery requires a repeatable sales process across collaboration, payments and infrastructure customers.

Product monetisation is the third test. Investors should look for named Iris and Prognosis Elevate customers, contract values where material, subscription contribution and evidence that these products improve renewal or expansion activity.

Cash discipline will remain equally important. Integrated Research has enough liquidity to fund its strategy, but management must establish a path toward EBITDA breakeven before the balance-sheet advantage begins eroding.

Integrated Research enters FY2027 with valuable technology, established global customers and a cash balance almost equal to its market capitalisation. What has not yet been established is whether its product-led transition can reverse revenue decline. The thesis will strengthen if renewal performance stabilises, Iris and Elevate generate measurable sales and EBITDA moves toward breakeven while cash remains broadly intact. It will weaken if new-product adoption remains slow and recurring revenue churn continues to exceed new-business growth.

What are the key takeaways from Integrated Research’s FY2026 trading update?

• Integrated Research expects FY2026 statutory revenue of A$56 million to A$58 million, approximately 17% below the previous year.
• Pro forma revenue is expected to fall 13% to between A$64 million and A$66 million, confirming that weakness extended beyond accounting timing.
• The company expects an EBITDA loss of A$2 million to A$4 million after softer renewals, slower second-half new business, credit-loss provisions and foreign exchange impacts.
• Integrated Research’s cash balance increased 27% to A$51.7 million at June 30, 2026.
• Cash equated to approximately A$0.286 per share, compared with the July 24 closing price of A$0.295.
• Integrated Research shares fell 3.28% on the announcement day but remained above their five-day and one-month levels.
• Iris and Prognosis Elevate are central to management’s attempt to create a more scalable, cloud-delivered and artificial intelligence-supported product portfolio.
• The product strategy has commercial logic, but FY2026 results show that new offerings have not yet offset recurring revenue churn.
• The August preliminary results should clarify cash conversion, credit-loss provisions and the cost of the product investment programme.
• FY2027 success depends on improved renewals, stronger new-business contract value, measurable Iris and Elevate sales and progress toward EBITDA breakeven.